Detalhe da pesquisa
1.
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
Br J Cancer
; 129(6): 1022-1031, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37507543
2.
The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells.
Invest New Drugs
; 39(2): 587-594, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33052557
3.
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A.
Invest New Drugs
; 38(5): 1365-1372, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32318883
4.
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
Invest New Drugs
; 36(4): 581-589, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29396630
5.
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
BMC Cancer
; 18(1): 965, 2018 Oct 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30305055
6.
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.
PLoS One
; 18(3): e0282512, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36920947
7.
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer.
NPJ Breast Cancer
; 9(1): 72, 2023 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37758711
8.
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Breast Cancer Res Treat
; 136(3): 717-27, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23117852
9.
Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer.
Cancer Drug Resist
; 5(3): 560-576, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36176752
10.
Precision Medicine and Novel Therapeutic Strategies in Detection and Treatment of Cancer: Highlights from the 58th IACR Annual Conference.
Cancers (Basel)
; 14(24)2022 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36551698
11.
A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin.
J Pers Med
; 12(8)2022 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36013226
12.
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Clin Cancer Res
; 27(3): 807-818, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33122343
13.
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.
Oncogene
; 39(14): 3028-3040, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32042115
14.
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer.
Ther Adv Med Oncol
; 12: 1758835919897546, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32064003
15.
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.
Cancers (Basel)
; 11(4)2019 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30999598
16.
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
J Transl Med
; 6: 53, 2008 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-18823558
17.
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.
BMC Cancer
; 8: 9, 2008 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-18199328
18.
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.
Ther Adv Med Oncol
; 10: 1758834017746040, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29383036
19.
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
Oncotarget
; 8(49): 85120-85135, 2017 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29156708
20.
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
Oncotarget
; 7(46): 75518-75525, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27776352